After an average of 3.6 years of follow-up, DPP4 inhibitors users had a significantly lower risk of acute kidney injury (HR = 0.57; 95% CI 0.53–0.61) and acute kidney injury requiring dialysis (HR = 0.57; 95% CI 0.49–0.66)11. This evidence concerns the gene DPP4 and acute kidney injury.